Report cover image

Hyperphosphatemia - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 50 Pages
SKU # DEL18679644

Description

Hyperphosphatemia - Pipeline Insight, 2024



DelveInsight’s, “Hyperphosphatemia - Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Hyperphosphatemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Hyperphosphatemia Understanding

Hyperphosphatemia: Overview

Hyperphosphatemia or even serum phosphate levels within the “normal laboratory range” are highly associated with increased cardiovascular disease risk and mortality in the general population and patients suffering from chronic kidney disease (CKD). As the kidney function declines, serum phosphate levels rise and subsequently induce the development of hypertension, vascular calcification, cardiac valvular calcification, atherosclerosis, left ventricular hypertrophy and myocardial fibrosis by distinct mechanisms. Therefore, phosphate is considered as a promising therapeutic target to improve the cardiovascular outcome in CKD patients. The current therapeutic strategies are based on dietary and pharmacological reduction of serum phosphate levels to prevent hyperphosphatemia in CKD patients.

""Hyperphosphatemia - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hyperphosphatemia pipeline landscape is provided which includes the disease overview and Hyperphosphatemia treatment guidelines. The assessment part of the report embraces, in depth Hyperphosphatemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hyperphosphatemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Hyperphosphatemia R&D. The therapies under development are focused on novel approaches to treat/improve Hyperphosphatemia.
Hyperphosphatemia Emerging Drugs Chapters

This segment of the Hyperphosphatemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hyperphosphatemia Emerging Drugs
  • FC818 (ferric citrate): PUMC Pharmaceutical
FC818 is a novel non-calcium-based phosphate binder. One Phase I and two pivotal Phase II clinical trials showed FC818 to be an effective and safe treatment for lowering and/or maintaining serum phosphorus levels <5.5 mg/dL in ESRD patients with hyperphosphatemia. The drug is currently in Phase III stage of clinical trial evaluation to treat Hyperphosphataemia.
  • VS 505: Shanghai Alebund Pharmaceuticals
VS 505 is a phosphate binding modulator being developed by Shanghai Alebund Pharmaceuticals for the treatment of Hyperphosphataemia.. The drug is currently in Phase II stage of clinical trial evaluation to treat Hyperphosphataemia.

Further product details are provided in the report……..

Hyperphosphatemia: Therapeutic Assessment

This segment of the report provides insights about the different Hyperphosphatemia drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players in Hyperphosphatemia
There are approx. 15+ key companies which are developing the therapies for Hyperphosphatemia. The companies which have their Hyperphosphatemia drug candidates in the most advanced stage, i.e. phase III include, PUMC Pharmaceutical.
  • Phases
DelveInsight’s report covers around 15+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Hyperphosphatemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hyperphosphatemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hyperphosphatemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hyperphosphatemia drugs.

Hyperphosphatemia Report Insights
  • Hyperphosphatemia Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Hyperphosphatemia Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Hyperphosphatemia drugs?
  • How many Hyperphosphatemia drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hyperphosphatemia?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hyperphosphatemia therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Hyperphosphatemia and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • PUMC Pharmaceutical
  • Shanghai Alebund Pharmaceuticals
  • Ardelyx
  • Kyowa Kirin
  • Phosphate Therapeutics
  • Liaoning Grand Nuokang Biopharmaceutical Co., Ltd.
  • Chugai Pharmaceutical
  • Keryx Biopharmaceuticals
  • Panion & BF Biotech Inc.
  • Sinomune Pharmaceutical
  • Daiichi Sankyo
  • J-Pharma
  • OPKO Renal
  • Altair Nanotechnologies
  • China Nuokang Bio-Pharmaceutical
  • Unicycive Therapeutics
Key Products
  • FC818 (ferric citrate)
  • VS 505
  • Tenapanor
  • PT20
  • EOS789
  • DS-2330b
  • JPH 101
  • Fermagate
  • Lanthanum dioxycarbonate
  • Lanthanum polystyrene sulfonic acid

Table of Contents

50 Pages
Introduction
Executive Summary
Hyperphosphatemia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Hyperphosphatemia – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
FC 818: PUMC Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
VS 505: Shanghai Alebund Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Hyperphosphatemia Key Companies
Hyperphosphatemia Key Products
Hyperphosphatemia- Unmet Needs
Hyperphosphatemia- Market Drivers and Barriers
Hyperphosphatemia- Future Perspectives and Conclusion
Hyperphosphatemia Analyst Views
Hyperphosphatemia Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us